Welireg Dosage

Generic name: BELZUTIFAN 40mg
Dosage form: tablet, film coated
Drug class: Miscellaneous antineoplastics

Medically reviewed by Drugs.com. Last updated on May 14, 2025.

Recommended Dosage

The recommended dosage of WELIREG in adult patients is 120 mg administered orally once daily.

The recommended dosage of WELIREG in pediatric patients 12 years and older is based on bodyweight:

Patients weighing ≥ 40 kg: 120 mg orally once daily
Patients weighing < 40 kg: 80 mg orally once daily

Continue WELIREG until disease progression or unacceptable toxicity.

WELIREG should be taken at the same time each day and may be taken with or without food.

Advise patients to swallow tablets whole. Do not chew, crush, or split WELIREG prior to swallowing.

If a dose of WELIREG is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for WELIREG the next day. Do not take extra tablets to make up for the missed dose.

If vomiting occurs any time after taking WELIREG, do not retake the dose. Take the next dose on the next day.

Dosage Modifications for Adverse Reactions

Dosage modifications for WELIREG for adverse reactions are summarized in Table 1.

The recommended dose reductions are:

First dose reduction: WELIREG 80 mg orally once daily
Second dose reduction: WELIREG 40 mg orally once daily
Third dose reduction: Permanently discontinue

Table 1: Recommended Dosage Modifications for Adverse Reactions
Adverse Reaction	Severity	Dosage Modification
Anemia	Hemoglobin <8 g/dL or transfusion indicated	Withhold until hemoglobin ≥8g/dL. Resume at the same or reduced dose; or discontinue depending on the severity of anemia.
Anemia	Life-threatening or urgent intervention indicated	Withhold until hemoglobin ≥8g/dL. Resume at a reduced dose or permanently discontinue.
Hypoxia	Decreased oxygen saturation with exercise (e.g., pulse oximeter <88%)	Consider withholding until resolved. Resume at the same dose or at a reduced dose depending on the severity of hypoxia.
	Decreased oxygen saturation at rest (e.g., pulse oximeter <88% or PaO2 ≤55 mm Hg) or urgent intervention indicated	Withhold until resolved. Resume at reduced dose or discontinue depending on the severity of hypoxia.
	Life-threatening or recurrent symptomatic hypoxia	Permanently discontinue.
Other Adverse Reactions	Grade 3	Withhold dosing until resolved to ≤ Grade 2. Consider resuming at a reduced dose (reduce by 40 mg). Permanently discontinue upon recurrence of Grade 3.
Other Adverse Reactions	Grade 4	Permanently discontinue.

More about Welireg (belzutifan)

Patient resources

Welireg drug information

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

Review this drug

Welireg Dosage

Recommended Dosage

Dosage Modifications for Adverse Reactions

More about Welireg (belzutifan)

Patient resources

Professional resources

Related treatment guides

See also:

Keytruda

Labetalol

Ozempic

Avastin

Inderal

Opdivo

Cabometyx

Afinitor

Phentolamine

Lenvatinib

Further information